Genetic Testing Firms May Retreat From Uncertain Regulatory Path – Q&A
This article was originally published in The Gray Sheet
Executive Summary
For targeted diagnostics, such as those that predict a person's responsiveness to a drug or treatment, regulatory uncertainty could be driving away investment, says the head of one leading genomic testing firm
You may also be interested in...
Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests, while diagnostics companies are split on the issue
QUOTED. 25 November 2020. Ricki Chase.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
US FDA’s 2020 User Fee Calendar Still Holds Promise Of Merry Novel Approval Count
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Need a specific report? 1000+ reports available
Buy Reports